Dissecting Piramal’s Damages Award In Sensipar Case
A legal expert details how Piramal Healthcare could turn the tables and secure damages in the litigation pertaining to its generic version of Amgen's Sensipar, a case which saw multiple at-risk launches.
You may also be interested in...
Dr Reddy’s Laboratories has launched a generic version of Sensipar in the US, the former blockbuster to treat hyperparathyroidism, with originator Amgen having previously been involved in multiple intellectual property fights over agreements with ANDA sponsors Teva and Cipla.
Cipla launched its generic version of Amgen’s Sensipar ‘at risk’ in March last year after suing the originator and Teva over an earlier agreement between the pair. The suit has now been settled, although claims against Teva remain standing.
Piramal halted sales of its generic version of Amgen’s Sensipar following a US court order that also required Amgen to furnish a $39m bond. The Sensipar generic launch landscape continues to be complex with multiple legal challenges, including those from Cipla and Sun at various stages.